Back to Search
Start Over
Maresin-1 Ameliorates Sepsis-Induced Microglial Activation Through Modulation of the P38 MAPK Pathway.
- Source :
-
Neurochemical research [Neurochem Res] 2024 Nov 20; Vol. 50 (1), pp. 26. Date of Electronic Publication: 2024 Nov 20. - Publication Year :
- 2024
-
Abstract
- Sepsis is a life-threatening disease characterized by a dysregulated immune response to infection, often leading to neuroinflammation. As a known immunomodulator, Maresin-1 (MaR1) may have potential applications in the treatment of sepsis-induced neuroinflammation, but its effects in this context are unknown. We used a mouse cecum ligation and puncture (CLP)-induced sepsis model and an in vitro lipopolysaccharide (LPS)-induced neuroinflammatory model of BV2 microglia. Expression of microglial cell markers (IBA1, CD11B, CD68, CD86 and CD206) and pro-inflammatory markers (iNOS and COX2) was assessed. The role of MaR1 in regulating the P38 MAPK pathway was explored using the P38 MAPK inhibitor SB203580. In the CLP model, an increased proportion of M1-type microglia was observed, and MaR1 was able to reverse it. However, the combination of SB203580 and MaR1 did not enhance the therapeutic effect compared to SB20580 alone. In vitro experiments, MaR1 inhibited LPS-induced P38 MAPK nuclear translocation and decreased the expression of pro-inflammatory markers such as iNOS and COX2. As with the animal results, no stacking effect could be obtained with the co-administration of SB203580 and MaR1. Our findings suggest that MaR1 attenuates sepsis-induced neuroinflammation mainly by inhibiting phosphorylation of P38 MAPK in microglial cells. This suggests that MaR1 may have a potential therapeutic role in the treatment of sepsis neuroinflammation.<br />Competing Interests: Declarations. Ethical Approval: All experimental procedures were approved by the Ethics Committee for Animal Experiments of Huazhong University of Science and Technology and were performed in accordance with the standards for the care and use of laboratory animals at this institution. Competing Interests: The authors declare no competing interests.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Subjects :
- Animals
Male
Mice
Mice, Inbred C57BL
Pyridines pharmacology
Pyridines therapeutic use
Imidazoles pharmacology
Imidazoles therapeutic use
Cell Line
Neuroinflammatory Diseases drug therapy
Neuroinflammatory Diseases metabolism
MAP Kinase Signaling System drug effects
MAP Kinase Signaling System physiology
Microglia drug effects
Microglia metabolism
Sepsis drug therapy
Sepsis metabolism
p38 Mitogen-Activated Protein Kinases metabolism
Lipopolysaccharides toxicity
Docosahexaenoic Acids pharmacology
Docosahexaenoic Acids therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1573-6903
- Volume :
- 50
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Neurochemical research
- Publication Type :
- Academic Journal
- Accession number :
- 39565476
- Full Text :
- https://doi.org/10.1007/s11064-024-04280-z